At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 17 enrolled
Drug / intervention
ACZ885drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS)
In Brief
A Phase 3 clinical trial evaluating ACZ885 for Cryopyrin-associated Periodic Syndromes and 3 related conditions. Completed, enrolled 17 participants across 12 sites in 7 countries.
Detailed Summary
This trial will assess the safety, efficacy and tolerability of ACZ885 in patients aged 4 years and younger with cryopyrin associated periodic syndromes (CAPS)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
CountriesBelgium, Canada, France, Germany, Spain, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedFeb 2011
Primary CompletionNov 2014
TodayJul 2026
First PostedFeb 24, 2011
Enrollment StartNov 1, 2010
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 15.4 years ago
Interventions
ACZ885drug